Article
New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting - 1 Apr 2024
Saw Stephanie P L, Le Xiuning, Hendriks Lizza E L, Remon Jordi
Abstract excerpt
Druggable oncogene-driven non-small cell lung cancer has led to innovative systemic treatment options, improving patients' outcome. This benefit is not only achieved in the metastatic setting but also in the postsurgical setting, such as in lung cancers harboring a common sensitizing EGFR mutation or ALK-rearrangement. To enhance the outcome of these patients, we need to understand the mechanisms of acquired...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.